Fuyuhiko Tamanoi, Ph.D.

Laboratory Address:
Molecular Science Building 2711, 2715
Los Angeles, CA 90095

Office Address:
405 Hilgard Avenue
Los Angeles, CA 90095

Work Address:
Molecular Science Building 2610A
BOX 951489
Los Angeles, CA 90095

Affiliations
Affiliations
Director, JCCC Signal Transduction and Therapeutics Program Area
Professor, Microbiology, Immunology & Molecular Genetics
Member, CTSI, California NanoSystems Institute, Cell & Developmental Biology GPB Home Area, Molecular Pharmacology GPB Home Area
Research Interests
The Ras-superfamily G-proteins play critical roles in cell growth and differentiation. Our research focuses on two members, Ras and Rheb. Ras is mutated in a wide range of human cancer including pancreatic, lung and colon cancers. This GTPase plays a central role in the growth factor signal transduction that is initiated by the activation of a receptor tyrosine kinase and results in the activation of multiple downstream pathways such as the Raf/Mek/Erk. Rheb is a novel and unique member of the Ras superfamily G-proteins. We have identified Rheb homologues in a number of organisms including fruit fly and yeasts, and defined unique features of this family of G-protein. Genetic studies using fission yeast as well as Drosophila showed that Rheb plays critical roles in cell growth, regulation of cell cycle and nutrient uptake. Rheb is a component of the TSC/TOR/S6K signaling pathway and is a direct activator of TOR. Rheb is downregulated by Tsc1/Tsc2 complex that acts as a GTPase activating protein (GAP) for Rheb. Mutations in the Tsc1 or Tsc2 gene leads to a genetic disorder called tuberous sclerosis that is associated with the appearance of benign tumors at multiple sites in the body. Our current effort is aimed at defining proteins involved in the Rheb signaling pathway. Both Ras and Rheb proteins are farnesylated, and the farnesylation is critical for their function. In particular, membrane association and transforming activity of Ras is dependent on its farnesylation. This led to the development of small molecule inhibitors of protein farnesyltransferase. These inhibitors, called FTIs, have recently been evaluated as anti-cancer drugs. FTIs block anchorage-independent growth of a wide variety of human cancer cells and animal studies have shown that FTIs inhibit the growth of tumors or even regress tumor growth. Our study focuses on the mechanism how FTI affects human cancer cells.
Biography:

Fuyu Tamanoi is a biochemist who has served on the UCLA School of Medicine and UCLA College faculty since he joined the Department of Microbiology, Immunology & Molecular Genetics in 1993. He became a full professor in 1997. Since 1996, he has been a Director of Signal Transduction Program Area at Jonsson Comprehensive Cancer Center. Dr. Tamanoi earned his B.S. and M.S. in Biochemistry at the University of Tokyo. He received PhD in Molecular Biology at Nagoya University in 1977. He was a postdoctoral fellow at Harvard Medical School, where he worked on bacteriophage DNA replication. From 1980 to 1985, he was a senior staff investigator at Cold Spring Harbor Laboratory, where he worked on adenovirus DNA replication. From 1985 to 1993, he was an Assistant Professor and then Associate Professor at the University of Chicago, where he initiated studies on lipid modification of the Ras family proteins. His laboratory research centers on signal transduction and signal transduction inhibitors. He is currently exploring ways to deliver signal transduction inhibitors using nanoparticles.

Publications
Patel Parthive H, Tamanoi Fuyuhiko Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. Methods in enzymology. 2006; 407(10): 443-54.
Davies Brandon S J, Yang Shao H, Farber Emily, Lee Roger, Buck Suzanne B, Andres Douglas A, Spielmann H Peter, Agnew Brian J, Tamanoi Fuyuhiko, Fong Loren G, Young Stephen G Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. Journal of lipid research. 2009; 50(1): 126-34.
Urano Jun, Comiso Melissa J, Guo Lea, Aspuria Paul-Joseph, Deniskin Roman, Tabancay Angel P, Kato-Stankiewicz Juran, Tamanoi Fuyuhiko Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Molecular microbiology. 2005; 58(4): 1074-86.
Ferris Daniel P, Lu Jie, Gothard Chris, Yanes Rolando, Thomas Courtney R, Olsen John-Carl, Stoddart J Fraser, Tamanoi Fuyuhiko, Zink Jeffrey I Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small (Weinheim an der Bergstrasse, Germany). 2011; 7(13): 1816-26.
Gau Chia-Ling, Kato-Stankiewicz Juran, Jiang Chen, Miyamoto Susie, Guo Lea, Tamanoi Fuyuhiko Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Molecular cancer therapeutics. 2005; 4(6): 918-26.
Liong Monty, Lu Jie, Kovochich Michael, Xia Tian, Ruehm Stefan G, Nel Andre E, Tamanoi Fuyuhiko, Zink Jeffrey I Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS nano. 2008; 2(5): 889-96.
Xue Min, Zhong Xing, Shaposhnik Zory, Qu Yongquan, Tamanoi Fuyuhiko, Duan Xiangfeng, Zink Jeffrey I pH-Operated mechanized porous silicon nanoparticles. Journal of the American Chemical Society. 2011; 133(23): 8798-801.
Aspuria Paul-Joseph, Tamanoi Fuyuhiko The Rheb family of GTP-binding proteins. Cellular signalling. 2004; 16(10): 1105-12.
Lu Jie, Li Zongxi, Zink Jeffrey I, Tamanoi Fuyuhiko In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine : nanotechnology, biology, and medicine. 2011; 133(23): .
Watanabe Masaru, Fiji Hannah D G, Guo Lea, Chan Lai, Kinderman Sape S, Slamon Dennis J, Kwon Ohyun, Tamanoi Fuyuhiko Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. The Journal of biological chemistry. 2008; 283(15): 9571-9.
Tamanoi Fuyuhiko Ras signaling in yeast. Genes & cancer. 2011; 2(3): 210-5.
Clarke Steven, Tamanoi Fuyuhiko Fighting cancer by disrupting C-terminal methylation of signaling proteins. The Journal of clinical investigation. 2004; 113(4): 513-5.
Lu Jie, Choi Eunshil, Tamanoi Fuyuhiko, Zink Jeffrey I Light-activated nanoimpeller-controlled drug release in cancer cells. Small (Weinheim an der Bergstrasse, Germany). 2008; 4(4): 421-6.
Hardt Molly, Chantaravisoot Naphat, Tamanoi Fuyuhiko Activating mutations of TOR (target of rapamycin). Genes to cells : devoted to molecular & cellular mechanisms. 2011; 16(2): 141-51.
Tabancay Angel P, Gau Chia-Ling, Machado Iara M P, Uhlmann Erik J, Gutmann David H, Guo Lea, Tamanoi Fuyuhiko Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. The Journal of biological chemistry. 2003; 278(41): 39921-30.
Meng Huan, Xue Min, Xia Tian, Zhao Yan-Li, Tamanoi Fuyuhiko, Stoddart J Fraser, Zink Jeffrey I, Nel Andre E Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Journal of the American Chemical Society. 2010; 132(36): 12690-7.
Patel Parthive H, Thapar Nitika, Guo Lea, Martinez Monica, Maris John, Gau Chia-Ling, Lengyel Judith A, Tamanoi Fuyuhiko Drosophila Rheb GTPase is required for cell cycle progression and cell growth. Journal of cell science. 2003; 116(Pt 17): 3601-10.
Sato Tatsuhiro, Umetsu Akiko, Tamanoi Fuyuhiko Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. Methods in enzymology. 2008; 438(3): 307-20.
Lu Jie, Liong Monty, Li Zongxi, Zink Jeffrey I, Tamanoi Fuyuhiko Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small (Weinheim an der Bergstrasse, Germany). 2010; 6(16): 1794-805.
Lu Jie, Liong Monty, Zink Jeffrey I, Tamanoi Fuyuhiko Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small (Weinheim an der Bergstrasse, Germany). 2007; 3(8): 1341-6.
Kato-Stankiewicz Juran, Hakimi Irina, Zhi Gang, Zhang Jie, Serebriiskii Ilya, Guo Lea, Edamatsu Hironori, Koide Hiroshi, Menon Sanjay, Eckl Robert, Sakamuri Sukumar, Lu Yingchun, Chen Quin-Zene, Agarwal Seema, Baumbach William R, Golemis Erica A, Tamanoi Fuyuhiko, Khazak Vladimir Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99(22): 14398-403.
Aspuria Paul-Joseph, Sato Tatsuhiro, Tamanoi Fuyuhiko The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: temperature sensitive and constitutive active mutants of TOR. Cell cycle (Georgetown, Tex.). 2007; 6(14): 1692-5.
Hom Christopher, Lu Jie, Liong Monty, Luo Hanzhi, Li Zongxi, Zink Jeffrey I, Tamanoi Fuyuhiko Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small (Weinheim an der Bergstrasse, Germany). 2010; 6(11): 1185-90.
Castellano Sabrina, Fiji Hannah D G, Kinderman Sape S, Watanabe Masaru, Leon Pablo de, Tamanoi Fuyuhiko, Kwon Ohyun Small-molecule inhibitors of protein geranylgeranyltransferase type I. Journal of the American Chemical Society. 2007; 129(18): 5843-5.
Lu Jie, Liong Monty, Sherman Sean, Xia Tian, Kovochich Michael, Nel Andre E, Zink Jeffrey I, Tamanoi Fuyuhiko Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology : the journal at the intersection of nanotechnology, molecular biology, and biomedical sciences. 2007; 3(2): 89-95.
Chan Lai N, Hart Courtenay, Guo Lea, Nyberg Tamara, Davies Brandon S J, Fong Loren G, Young Stephen G, Agnew Brian J, Tamanoi Fuyuhiko A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis. 2009; 30(20): 3598-606.
Yu Fuqu, Harada Josephine N, Brown Helen J, Deng Hongyu, Song Moon Jung, Wu Ting-Ting, Kato-Stankiewicz Juran, Nelson Christian G, Vieira Jeffrey, Tamanoi Fuyuhiko, Chanda Sumit K, Sun Ren Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. PLoS pathogens. 2007; 3(3): e44.
Sato Tatsuhiro, Nakashima Akio, Guo Lea, Tamanoi Fuyuhiko Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. The Journal of biological chemistry. 2009; 284(19): 12783-91.
Urano Jun, Sato Tatsuhiro, Matsuo Tomohiko, Otsubo Yoko, Yamamoto Masayuki, Tamanoi Fuyuhiko Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(9): 3514-9.
Lu Jie, Chan Lai, Fiji Hannah D G, Dahl Russell, Kwon Ohyun, Tamanoi Fuyuhiko In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Molecular cancer therapeutics. 2009; 8(5): 1218-26.
Patel Parthive H, Tamanoi Fuyuhiko Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress. Journal of cell science. 2006; 119(Pt 20): 4285-92.
Klichko Yaroslav, Liong Monty, Choi Eunshil, Angelos Sarah, Nel Andre E, Stoddart J Fraser, Tamanoi Fuyuhiko, Zink Jeffrey I Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Journal of the American Ceramic Society. American Ceramic Society. 2009; 92(s1): s2-s10.
Hom Christopher, Lu Jie, Tamanoi Fuyuhiko Silica nanoparticles as a delivery system for nucleic acid-based reagents. Journal of materials chemistry. 2009; 19(35): 6308-6316.
Jiang Huaidong, Song Changyong, Chen Chien-Chun, Xu Rui, Raines Kevin S, Fahimian Benjamin P, Lu Chien-Hung, Lee Ting-Kuo, Nakashima Akio, Urano Jun, Ishikawa Tetsuya, Tamanoi Fuyuhiko, Miao Jianwei Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(25): 11234-9.
Nakashima Akio, Sato Tatsuhiro, Tamanoi Fuyuhiko Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. Journal of cell science. 2010; 123(Pt 5): 777-86.
Aspuria Paul-Joseph, Tamanoi Fuyuhiko The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Molecular genetics and genomics : MGG. 2008; 279(5): 441-50.
Uhlmann Erik J, Li Wen, Scheidenhelm Danielle K, Gau Chia-Ling, Tamanoi Fuyuhiko, Gutmann David H Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia. 2004; 47(2): 180-8.
Hamasaki Akiyuki, Naka Hayato, Tamanoi Fuyuhiko, Umezawa Kazuo, Otsuka Masami A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorganic & medicinal chemistry letters. 2003; 13(9): 1523-6.
Akhavan David, Pourzia Alexandra L, Nourian Alex A, Williams Kevin J, Nathanson David, Babic Ivan, Villa Genaro R, Tanaka Kazuhiro, Nael Ali, Yang Huijun, Dang Julie, Vinters Harry V, Yong William H, Flagg Mitchell, Tamanoi Fuyuhiko, Sasayama Takashi, James C David, Kornblum Harley I, Cloughesy Tim F, Cavenee Webster K, Bensinger Steven J, Mischel Paul S De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients. Cancer discovery. 2013; 3(5): 534-547.
Zimonjic Drazen B, Chan Lai N, Tripathi Veenu, Lu Jie, Kwon Ohyun, Popescu Nicholas C, Lowy Douglas R, Tamanoi Fuyuhiko In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. BMC cancer. 2013; 13(5): 198.
Yanes Rolando E, Tarn Derrick, Hwang Angela A, Ferris Daniel P, Sherman Sean P, Thomas Courtney R, Lu Jie, Pyle April D, Zink Jeffrey I, Tamanoi Fuyuhiko Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small (Weinheim an der Bergstrasse, Germany). 2013; 9(5): 697-704.
Hon Nick K, Shaposhnik Zory, Diebold Eric D, Tamanoi Fuyuhiko, Jalali Bahram Tailoring the biodegradability of porous silicon nanoparticles. Journal of biomedical materials research. Part A. 2012; 100(12): 3416-21.
Nakashima Akio, Otsubo Yoko, Yamashita Akira, Sato Tatsuhiro, Yamamoto Masayuki, Tamanoi Fuyuhiko Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. Journal of cell science. 2012; 125(Pt 23): 5840-9.
Lau Yuen A, Henderson Bryana L, Lu Jie, Ferris Daniel P, Tamanoi Fuyuhiko, Zink Jeffrey I Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Nanoscale. 2012; 4(11): 3482-9.
Yanes Rolando E, Tamanoi Fuyuhiko Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic delivery. 2012; 3(3): 389-404.
Rettig Matthew, Trinidad Kenny, Pezeshkpour G, Frost Patrick, Sharma Sherven, Moatamed Farhad, Tamanoi Fuyuhiko, Mortazavi Fariborz PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PloS one. 2012; 7(7): e42012.
Chan Lai N, Fiji Hannah D G, Watanabe Masaru, Kwon Ohyun, Tamanoi Fuyuhiko Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. PloS one. 2011; 6(10): e26135.
Sato Tatsuhiro, Nakashima Akio, Tamanoi Fuyuhiko [Rheb-mTOR signaling pathway involved in tumor formation]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme. 2010; 55(1): 11-7.
Zhou Jun, Vos Chantal Chanel, Gjyrezi Ada, Yoshida Minoru, Khuri Fadlo R, Tamanoi Fuyuhiko, Giannakakou Paraskevi The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. The Journal of biological chemistry. 2009; 284(15): 9648-55.
Short John D, Houston Kevin D, Dere Ruhee, Cai Sheng-Li, Kim Jinhee, Johnson Charles L, Broaddus Russell R, Shen Jianjun, Miyamoto Susie, Tamanoi Fuyuhiko, Kwiatkowski David, Mills Gordon B, Walker Cheryl Lyn AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer research. 2008; 68(16): 6496-506.
Ikeda Kyoko, Morigasaki Susumu, Tatebe Hisashi, Tamanoi Fuyuhiko, Shiozaki Kazuhiro Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell cycle (Georgetown, Tex.). 2008; 7(3): 358-64.
Matsuo Tomohiko, Otsubo Yoko, Urano Jun, Tamanoi Fuyuhiko, Yamamoto Masayuki Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast. Molecular and cellular biology. 2007; 27(8): 3154-64.
Gelb Michael H, Brunsveld Lucas, Hrycyna Christine A, Michaelis Susan, Tamanoi Fuyuhiko, Van Voorhis Wesley C, Waldmann Herbert Therapeutic intervention based on protein prenylation and associated modifications. Nature chemical biology. 2006; 2(10): 518-28.
Kho Yoonjung, Kim Sung Chan, Jiang Chen, Barma Deb, Kwon Sung Won, Cheng Jinke, Jaunbergs Janis, Weinbaum Carolyn, Tamanoi Fuyuhiko, Falck John, Zhao Yingming A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(34): 12479-84.
Théron Christophe, Gallud Audrey, Carcel Carole, Gary-Bobo Magali, Maynadier Marie, Garcia Marcel, Lu Jie, Tamanoi Fuyuhiko, Zink Jeffrey I, Wong Chi Man Michel Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Chemistry (Weinheim an der Bergstrasse, Germany). 2014; 20(30): 9372-80.
Nakashima Akio, Kamada Shinji, Tamanoi Fuyuhiko, Kikkawa Ushio Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biology open. 2014; 3(6): 542-52.
Croissant Jonas G, Fatieiev Yevhen, Omar Haneen, Anjum Dalaver H, Gurinov Andrey, Lu Jie, Tamanoi Fuyuhiko, Zink Jeffrey I, Khashab Niveen M Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry (Weinheim an der Bergstrasse, Germany). 2016; 22(28): 9607-15.
Tamanoi Fuyuhiko [Recent developments in targeted therapy for cancers and drug discovery]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 2014; 143(5): 236-42.
Croissant Jonas, Chaix Arnaud, Mongin Olivier, Wang Miao, Clément Sébastien, Raehm Laurence, Durand Jean-Olivier, Hugues Vincent, Blanchard-Desce Mireille, Maynadier Marie, Gallud Audrey, Gary-Bobo Magali, Garcia Marcel, Lu Jie, Tamanoi Fuyuhiko, Ferris Daniel P, Tarn Derrick, Zink Jeffrey I Two-photon-triggered drug delivery via fluorescent nanovalves. Small (Weinheim an der Bergstrasse, Germany). 2014; 10(9): 1752-5.
Croissant Jonas G, Fatieiev Yevhen, Julfakyan Khachatur, Lu Jie, Emwas Abdul-Hamid, Anjum Dalaver H, Omar Haneen, Tamanoi Fuyuhiko, Zink Jeffrey I, Khashab Niveen M Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry (Weinheim an der Bergstrasse, Germany). 2016; 22(28): .
Coffman Kimberly, Yang Bing, Lu Jie, Tetlow Ashley L, Pelliccio Emelia, Lu Shan, Guo Da-Chuan, Tang Chun, Dong Meng-Qiu, Tamanoi Fuyuhiko Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. The Journal of biological chemistry. 2014; 289(8): 4723-34.
Croissant Jonas G, Zhang Dingyuan, Alsaiari Shahad, Lu Jie, Deng Lin, Tamanoi Fuyuhiko, AlMalik Abdulaziz M, Zink Jeffrey I, Khashab Niveen M Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Journal of controlled release : official journal of the Controlled Release Society. 2016; 229(28): 183-91.
Bathaie S Zahra, Tamanoi Fuyuhiko Preface. The Enzymes. 2014; 36(8): xiii.
Zahra Bathaie S, Ashrafi Mahboobeh, Azizian Mahshid, Tamanoi Fuyuhiko Mevalonate Pathway and Human Cancers. Current molecular pharmacology. 2016; 229(28): .
Bathaie S Zahra, Bolhassani Azam, Tamanoi Fuyuhiko Anticancer Effect and Molecular Targets of Saffron Carotenoids. The Enzymes. 2014; 36(8): 57-86.
Kaguni Laurie S, Oliveira Marcos Túlio, Tamanoi Fuyuhiko Preface. The Enzymes. 2016; 39(28): xi.
Bathaie S Zahra, Tamanoi Fuyuhiko Introduction. The Enzymes. 2014; 36(8): 1-6.
Mekaru Harutaka, Lu Jie, Tamanoi Fuyuhiko Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. Advanced drug delivery reviews. 2015; 95(28): 40-9.
Machinda Yasunori, Lin Chentao, Tamanoi Fuyuhiko Preface. The Enzymes. 2014; 35(8): xi-xiii.
Finlay James, Roberts Cai M, Dong Juyao, Zink Jeffrey I, Tamanoi Fuyuhiko, Glackin Carlotta A Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine : nanotechnology, biology, and medicine. 2015; 11(7): 1657-66.
Croissant Jonas, Maynadier Marie, Gallud Audrey, Peindy N'dongo Harmel, Nyalosaso Jeff L, Derrien Gaëlle, Charnay Clarence, Durand Jean-Olivier, Raehm Laurence, Serein-Spirau Françoise, Cheminet Nathalie, Jarrosson Thibaut, Mongin Olivier, Blanchard-Desce Mireille, Gary-Bobo Magali, Garcia Marcel, Lu Jie, Tamanoi Fuyuhiko, Tarn Derrick, Guardado-Alvarez Tania M, Zink Jeffrey I Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angewandte Chemie (International ed. in English). 2013; 52(51): 13813-7.
Chantaravisoot Naphat, Wongkongkathep Piriya, Loo Joseph A, Mischel Paul S, Tamanoi Fuyuhiko Significance of filamin A in mTORC2 function in glioblastoma. Molecular cancer. 2015; 14(7): 127.
Tamanoi Fuyuhiko, Der Channing J Inhibitors of the Ras superfamily of small G-proteins. Preface. The Enzymes. 2013; 34 Pt. B(51): ix.
Mortazavi Fariborz, Lu Jie, Phan Ryan, Lewis Michael, Trinidad Kenny, Aljilani Amir, Pezeshkpour Gholamhossein, Tamanoi Fuyuhiko Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. BMC cancer. 2015; 15(7): 381.
Hwang Angela A, Lu Jie, Tamanoi Fuyuhiko, Zink Jeffrey I Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small (Weinheim an der Bergstrasse, Germany). 2015; 11(3): 319-28.
Tamanoi Fuyuhiko, Lu Jie Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. The Enzymes. 2013; 34 Pt. B(51): 181-200.
Sato Tatsuhiro, Akasu Hitomi, Shimono Wataru, Matsu Chisa, Fujiwara Yuki, Shibagaki Yoshio, Heard Jeffrey J, Tamanoi Fuyuhiko, Hattori Seisuke Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. The Journal of biological chemistry. 2015; 290(2): 1096-105.
Khazak Vladimir, Eyrisch Susanne, Kato Juran, Tamanoi Fuyuhiko, Golemis Erica A A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. The Enzymes. 2013; 33 Pt A(51): 213-48.
Tamanoi Fuyuhiko Preface. The Enzymes. 2013; 33 Pt A(51): ix.
Inoue Keizo, Stafforini Diana, Tamanoi Fuyuhiko Preface. The Enzymes. 2015; 38(2): xi.
Tetlow Ashley L, Tamanoi Fuyuhiko The Ras superfamily G-proteins. The Enzymes. 2013; 33 Pt A(51): 1-14.
Bathaie S Zahra, Tamanoi Fuyuhiko Preface. The Enzymes. 2015; 37(2): xiii.
Chanfreau Guillaume, Tamanoi Fuyuhiko Preface. The Enzymes. 2012; 31(51): x-xii.
Bathaie S Zahra, Faridi Nasim, Nasimian Ahmad, Heidarzadeh Hamid, Tamanoi Fuyuhiko How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?. The Enzymes. 2015; 37(2): 1-42.
Nakashima Akio, Tamanoi Fuyuhiko Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. The Enzymes. 2012; 28(51): 167-187.
Lu Jie, Yoshimura Kohei, Goto Koichi, Lee Craig, Hamura Ken, Kwon Ohyun, Tamanoi Fuyuhiko Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. PloS one. 2015; 10(9): e0137595.
Parmar Nitika, Tamanoi Fuyuhiko Rheb G-Proteins and the Activation of mTORC1. The Enzymes. 2010; 27(51): 39-56.
Heard Jeffrey J, Fong Valerie, Bathaie S Zahra, Tamanoi Fuyuhiko Recent progress in the study of the Rheb family GTPases. Cellular signalling. 2014; 26(9): 1950-7.